Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Lactoferrin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlaniv../e..
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Curcumin for COVID-19: real-time meta analysis of 10 studies
Covid Analysis, January 25, 2022, DRAFT
https://c19curcumin.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dound (RCT) 33% 0.67 [0.54-0.82] 6 pt. scale 100 (n) 100 (n) CT​1 Improvement, RR [CI] Treatment Control Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Saber-Moghaddam 38% 0.62 [0.39-0.96] no recov. 11/21 17/20 Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Pawar (DB RCT) 60% 0.40 [0.09-1.75] death 2/15 5/15 Pawar (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 Pawar (DB RCT) 67% 0.33 [0.01-7.87] death 0/30 1/30 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Ahmadi (DB RCT) 21% 0.79 [0.48-1.31] recov. time 30 (n) 30 (n) Sankhe (RCT) 89% 0.11 [0.01-2.03] death 0/87 4/87 CT​1 Sankhe (RCT) 75% 0.25 [0.03-2.19] ventilation 1/87 4/87 CT​1 Sankhe (RCT) 46% 0.54 [0.35-0.76] no recov. 29/87 60/87 CT​1 Sankhe (RCT) 10% 0.90 [0.71-1.15] hosp. time 87 (n) 87 (n) CT​1 Majeed (DB RCT) 66% 0.34 [0.01-8.09] ventilation 0/45 1/47 CT​1 Majeed (DB RCT) 80% 0.20 [0.01-4.13] hosp. 0/45 2/47 CT​1 Majeed (DB RCT) 43% 0.57 [0.39-0.84] no recov. 45 (n) 47 (n) CT​1 Majeed (DB RCT) 25% 0.75 [0.56-1.01] no recov. 26/45 36/47 CT​1 Majeed (DB RCT) 6% 0.94 [0.80-1.10] viral time 45 (n) 47 (n) CT​1 Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Tahmasebi (DB RCT) 83% 0.17 [0.02-1.32] death 1/40 6/40 Tahmasebi (DB RCT) 67% 0.33 [0.01-7.72] death 0/20 1/20 Tahmasebi (DB RCT) 80% 0.20 [0.03-1.56] death 1/20 5/20 Hassania.. (DB RCT) -46% 1.46 [0.01-329] SpO2 imp. 20 (n) 20 (n) Asadirad (RCT) 26% 0.74 [0.26-2.12] death 5/27 6/24 Asadirad (RCT) 50% 0.50 [0.14-1.82] progression 3/30 6/30 Asadirad (RCT) 45% 0.55 [0.27-1.09] no recov. 8/27 13/24 Asadirad (RCT) 29% 0.71 [0.22-2.35] no recov. 4/27 5/24 Asadirad (RCT) 41% 0.59 [0.25-1.42] no recov. 6/27 9/24 Asadirad (RCT) 37% 0.63 [0.23-1.74] no recov. 5/27 7/24 Asadirad (RCT) 20% 0.80 [0.58-1.10] no recov. 18/27 20/24 curcumin COVID-19 outcomes c19curcumin.com Jan 25, 2022 1 CT: study uses combined treatment Favors curcumin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit